These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 27273997

  • 1. [New insight in pathogenesis of podocyte disfunction in minimal change disease].
    Liu S, Chen J.
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 Mar; 45(2):214-8. PubMed ID: 27273997
    [Abstract] [Full Text] [Related]

  • 2. Reduced podocin expression in minimal change disease and focal segmental glomerulosclerosis is related to the level of proteinuria.
    Agrawal V, Prasad N, Jain M, Pandey R.
    Clin Exp Nephrol; 2013 Dec; 17(6):811-8. PubMed ID: 23377573
    [Abstract] [Full Text] [Related]

  • 3. Toll-like receptor 3 ligand, polyIC, induces proteinuria and glomerular CD80, and increases urinary CD80 in mice.
    Ishimoto T, Shimada M, Gabriela G, Kosugi T, Sato W, Lee PY, Lanaspa MA, Rivard C, Maruyama S, Garin EH, Johnson RJ.
    Nephrol Dial Transplant; 2013 Jun; 28(6):1439-46. PubMed ID: 23262434
    [Abstract] [Full Text] [Related]

  • 4. New insights into human minimal change disease: lessons from animal models.
    Chugh SS, Clement LC, Macé C.
    Am J Kidney Dis; 2012 Feb; 59(2):284-92. PubMed ID: 21974967
    [Abstract] [Full Text] [Related]

  • 5. Angiopoietin-Like-4, a Potential Target of Tacrolimus, Predicts Earlier Podocyte Injury in Minimal Change Disease.
    Li JS, Chen X, Peng L, Wei SY, Zhao SL, Diao TT, He YX, Liu F, Wei QJ, Zhang QF, Li B.
    PLoS One; 2015 Feb; 10(9):e0137049. PubMed ID: 26352670
    [Abstract] [Full Text] [Related]

  • 6. Minimal change disease: a "two-hit" podocyte immune disorder?
    Shimada M, Araya C, Rivard C, Ishimoto T, Johnson RJ, Garin EH.
    Pediatr Nephrol; 2011 Apr; 26(4):645-9. PubMed ID: 21052729
    [Abstract] [Full Text] [Related]

  • 7. "Idiopathic" minimal change nephrotic syndrome: a podocyte mystery nears the end.
    Chugh SS, Clement LC.
    Am J Physiol Renal Physiol; 2023 Dec 01; 325(6):F685-F694. PubMed ID: 37795536
    [Abstract] [Full Text] [Related]

  • 8. Calcineurin inhibitors ameliorate PAN-induced podocyte injury through the NFAT-Angptl4 pathway.
    Shen X, Zhang Y, Lin C, Weng C, Wang Y, Feng S, Wang C, Shao X, Lin W, Li B, Wang H, Chen J, Jiang H.
    J Pathol; 2020 Nov 01; 252(3):227-238. PubMed ID: 32686149
    [Abstract] [Full Text] [Related]

  • 9. Glomerular endothelial cells and podocytes can express CD80 in patients with minimal change disease during relapse.
    Cara-Fuentes G, Venkatareddy M, Verma R, Segarra A, Cleuren AC, Martínez-Ramos A, Johnson RJ, Garg P.
    Pediatr Nephrol; 2020 Oct 01; 35(10):1887-1896. PubMed ID: 32399663
    [Abstract] [Full Text] [Related]

  • 10. β1-Integrin blockade prevents podocyte injury in experimental models of minimal change disease.
    Cara-Fuentes G, Verma R, Venkatareddy M, Bauer C, Piani F, Aksoy ST, Vazzalwar N, Garcia GE, Banks M, Ordoñez FA, de Lucas-Collantes C, Bjornstad P, González Rodríguez JD, Johnson RJ, Garg P.
    Nefrologia (Engl Ed); 2024 Oct 01; 44(1):90-99. PubMed ID: 37150673
    [Abstract] [Full Text] [Related]

  • 11. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome.
    Clement LC, Avila-Casado C, Macé C, Soria E, Bakker WW, Kersten S, Chugh SS.
    Nat Med; 2011 Jan 01; 17(1):117-22. PubMed ID: 21151138
    [Abstract] [Full Text] [Related]

  • 12. Podocyte-specific NF-κB inhibition ameliorates proteinuria in adriamycin-induced nephropathy in mice.
    Yamashita M, Yoshida T, Suzuki S, Homma K, Hayashi M.
    Clin Exp Nephrol; 2017 Feb 01; 21(1):16-26. PubMed ID: 27089875
    [Abstract] [Full Text] [Related]

  • 13. Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?
    Novelli R, Gagliardini E, Ruggiero B, Benigni A, Remuzzi G.
    Am J Physiol Renal Physiol; 2016 Mar 01; 310(5):F335-41. PubMed ID: 26697986
    [Abstract] [Full Text] [Related]

  • 14. Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms.
    Cara-Fuentes G, Clapp WL, Johnson RJ, Garin EH.
    Pediatr Nephrol; 2016 Dec 01; 31(12):2179-2189. PubMed ID: 27384691
    [Abstract] [Full Text] [Related]

  • 15. Synaptopodin expression in idiopathic nephrotic syndrome of childhood.
    Srivastava T, Garola RE, Whiting JM, Alon US.
    Kidney Int; 2001 Jan 01; 59(1):118-25. PubMed ID: 11135064
    [Abstract] [Full Text] [Related]

  • 16. CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease.
    Teh YM, Lim SK, Jusoh N, Osman K, Mualif SA.
    Biomed Res Int; 2021 Jan 01; 2021():6671552. PubMed ID: 33506028
    [Abstract] [Full Text] [Related]

  • 17. In situ evaluation of podocytes in patients with focal segmental glomerulosclerosis and minimal change disease.
    da Silva CA, Monteiro MLGDR, Araújo LS, Urzedo MG, Rocha LB, Dos Reis MA, Machado JR.
    PLoS One; 2020 Jan 01; 15(11):e0241745. PubMed ID: 33147279
    [Abstract] [Full Text] [Related]

  • 18. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats.
    Lai KW, Wei CL, Tan LK, Tan PH, Chiang GS, Lee CG, Jordan SC, Yap HK.
    J Am Soc Nephrol; 2007 May 01; 18(5):1476-85. PubMed ID: 17429054
    [Abstract] [Full Text] [Related]

  • 19. Intra-renal and urinary mRNA expression of podocyte-associated molecules for the estimation of glomerular podocyte loss.
    Wang G, Lai FM, Lai KB, Chow KM, Kwan BC, Li KT, Szeto CC.
    Ren Fail; 2010 Jan 01; 32(3):372-9. PubMed ID: 20370455
    [Abstract] [Full Text] [Related]

  • 20. Synaptopodin immunoexpression in steroid-responsive and steroid-resistant minimal change disease and focal segmental glomerulosclerosis.
    Wagrowska-Danilewicz M, Danilewicz M.
    Nefrologia; 2007 Jan 01; 27(6):710-5. PubMed ID: 18336100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.